Angiotensin II Type-1 Receptor Antibodies in Renal Transplant Recipients Associated with Ventricular and Endothelial Dysfunction: Preliminary Results.

L. Figuerola-Chaparro,¹ F. Davila-Radilla,¹ E. Cuevas,² L. Castillo-Martínez,¹ A. Orea-Tejeda,¹ J. Arreola-Guerra,² J. Alberu.²

¹Cardiology, Inst Nal Ciencias Medicas y Nutricion SZ, Mexico City, Mexico
²Transplantation, Inst Nal Ciencias Medicas y Nutricion SZ, Mexico City, Mexico.

Meeting: 2016 American Transplant Congress

Abstract number: B226

Keywords: Antibodies, Dyslipidemia, Echocardiography, Kidney transplantation

Session Information

Session Name: Poster Session B: Kidney: Cardiovascular and Metabolic

Session Type: Poster Session

Date: Sunday, June 12, 2016

Session Time: 6:00pm-7:00pm

Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Previous studies demonstrated the significance of angiotensin II type-1 receptor antibodies (AT1Rabs) in processes including hypertension, cardiac hypertrophy and renal fibrosis; information regarding ventricular and endothelial dysfunction is lacking and constitute the aim of this study. Methods: AT1Rabs were determined (CellTrend GmBH, One-Lambda) in pretransplant sera samples from renal transplant recipients (RTR); AT1Rabs titers ≥17U were considered positive. At a median of 42.9±9.07 mo posttransplantation endothelial function was measured by photoplethysmography (PPG) using the index waveform maximum amplitude time/total amplitude time (MAT/TT); a MAT/TT >30 was defined as endothelial dysfunction (ED). In order to evaluate cardiac function a transthoracic echocardiogram (TTE) was also performed pretransplant and posttransplant at a median of 24.8±15.9 mo, where the mean parameter valued was left ventricular ejection fraction (LVEF). Results: The study included 67 RTR with pre- and posttransplant TTE. Patients were divided in 2 groups according to AT1Rabs results (positive (+ve) (n=8) or negative (-ve) (n=59). A lower pre-transplant LVEF was found in AT1Rab+-ve RTR as well as a higher frequency of endothelial dysfunction compared to AT1Rab-ve RTR. Improvement in LVEF posttransplant occurred in both groups however LVEF continue being higher in the ATRabs-ve group. Also, dyslipidemia (defined according to ACC/AHA criteria) was significantly more frequent in AT1Rab+ive patients. There were no significant differences in the demographic characteristics between the groups (Table 1), neither in confounding factors for endothelial dysfunction.

Table 1	AT1Rabs+ve n=8	AT1Rabs-ve n=59	P
Age (yr)	34.3 (±10.5)	32.8 (±12.1)	0.71
Gender (male) %	70	53.2	0.3
Diabetes %	0	12.3	0.3
Hypertension %	42.9	50.9	0.7
Dyslipidemia %	85.7	24.6	0.003
LVEF (%) pretransplant	50 (±18)	61.8 (±9.8)	0.005
LVEF (%) posttransplant	59.1 (±14)	62.1 (±8)	0.009
ED (n=44)	2 (40)	4 (10)	0.13

Conclusions: There were lower pre- & posttransplant LVEF, a trend toward worse endothelial function and a significantly different frequency of dyslipidemia in RTR AT1Rabs+ve patients. Whether AT1Rabs represents a greater risk for CV outcome of this population remain to be defined.

CITATION INFORMATION: Figuerola-Chaparro L, Davila-Radilla F, Cuevas E, Castillo-Martínez L, Orea-Tejeda A, Arreola-Guerra J, Alberu J. Angiotensin II Type-1 Receptor Antibodies in Renal Transplant Recipients Associated with Ventricular and Endothelial Dysfunction: Preliminary Results. Am J Transplant. 2016;16 (suppl 3).

To cite this abstract in AMA style:

Figuerola-Chaparro L, Davila-Radilla F, Cuevas E, Castillo-Martínez L, Orea-Tejeda A, Arreola-Guerra J, Alberu J. Angiotensin II Type-1 Receptor Antibodies in Renal Transplant Recipients Associated with Ventricular and Endothelial Dysfunction: Preliminary Results. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/angiotensin-ii-type-1-receptor-antibodies-in-renal-transplant-recipients-associated-with-ventricular-and-endothelial-dysfunction-preliminary-results/. Accessed May 10, 2025.

« Back to 2016 American Transplant Congress